Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$21M Buy
63,600
+10,178
+19% +$3.36M 0.02% 930
2014
Q2
$16.8M Buy
53,422
+6,922
+15% +$2.08M 0.01% 987
2014
Q1
$14.2M Buy
46,500
+26,700
+135% +$8.48M 0.01% 1006
2013
Q4
$5.54M Buy
19,800
+11,100
+128% +$2.87M 0.01% 1770
2013
Q3
$2.1M Sell
8,700
-4,500
-34% -$1.01M ﹤0.01% 2523
2013
Q2
$2.84M Buy
+13,200
New +$2.82M ﹤0.01% 2164

Other funds holding BIIB

UBS's BIIB Position: Q3 2014 in Review

UBS increased its Biogen (BIIB) stake by 8.3% in Q3 2014, buying an estimated $4.28M and bringing the position to 168,877 shares worth $55.9M. The position accounts for 0.04% of the portfolio, ranked #465.

UBS first reported a position in BIIB in Q2 2013 and has held it in 6 quarters since. 818 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

  • UBS held 168,877 shares of Biogen worth $55.9M as of Q3 2014.
  • UBS bought 12,990 Biogen shares in Q3 2014, an estimated $4.28M.
  • Biogen made up 0.04% of UBS's portfolio in Q3 2014, its #465 holding.
  • UBS first reported a position in Biogen in Q2 2013 and has held it in 6 quarters since.
  • 818 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.